MedCity News May 25, 2020
Even with the Covid-19 crisis still underway, we can identify lessons that guide the road ahead and they include strategies like committing to greater diversification.
Seasoned medtech leaders have typically seen their companies through historic disruptions requiring rapid shifts in production, realignment of deliverables, reallocation of raw materials, and more. Whether this was in response to natural disasters, trade disputes, or some other significant disruption, experienced executive teams with well-devised contingency plans have traditionally managed to move forward in the face of challenge.
But unlike any disruption that has come before, Covid-19 has sent shockwaves rippling through the industry and economy, generating unprecedented challenges and uncertain repercussions. Medtech leaders and healthcare product-innovators have been scrambling to make sense of the...
Today's Sponsors
Today's Sponsor